Goldman Sachs
EBS icon

Goldman Sachs’s Emergent Biosolutions EBS Stock Holding History

Goldman Sachs’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-48,100
Closed -$1.75M – 7061
2016
Q1 		$1.75M Buy
+48,100
New +$1.7M ﹤0.01% 3606

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs's EBS Position: Q1 2026 in Review

Goldman Sachs increased its Emergent Biosolutions (EBS) stake by 9.7% in Q1 2026, buying an estimated $740K and bringing the position to 811,560 shares worth $6.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3415.

Goldman Sachs first reported a position in EBS in Q2 2013 and has held it in 52 quarters since. The position peaked at $80.7M in Q4 2020. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Goldman Sachs held 811,560 shares of Emergent Biosolutions worth $6.74M as of Q1 2026.
  • Goldman Sachs bought 71,460 Emergent Biosolutions shares in Q1 2026, an estimated $740K.
  • Emergent Biosolutions made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3415 holding.
  • Goldman Sachs first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Emergent Biosolutions position peaked at $80.7M in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.